how big is Ambalal Sarabhai?

As of Jun 06, Ambalal Sarabhai Enterprises Ltd has a market capitalization of 284.00 Cr, with recent net sales of 196.18 Cr and a net profit of 4.93 Cr. Shareholder's funds are 137.13 Cr, and total assets amount to 250.23 Cr.

Market Cap: As of Jun 06, Ambalal Sarabhai Enterprises Ltd has a market capitalization of 284.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported a sum of Net Sales of 196.18 Cr and a sum of Net Profit of 4.93 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: The balance sheet data is also on a Consolidated basis for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 137.13 Cr, while Total Assets amount to 250.23 Cr.

What does Ambalal Sarabhai do?

Ambalal Sarabhai Enterprises Ltd is a micro-cap Indian company in the Pharmaceuticals & Biotechnology sector, focusing on manufacturing and marketing pharmaceutical and diagnostic products. As of March 2025, it reported net sales of 65 Cr and a market cap of Rs 279 Cr.

Overview: <BR>Ambalal Sarabhai Enterprises Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, engaged in the manufacturing and marketing of pharmaceutical, molecular diagnostics, and electronics products.<BR><BR>History: <BR>Incorporated on June 5, 1978, Ambalal Sarabhai Enterprises Ltd is one of the oldest pharmaceutical healthcare companies in India. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 65 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 279 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.28 <BR>Return on Equity: 8.52% <BR>Price to Book: 2.02 <BR><BR>Contact Details: <BR>Address: Shanti Sadan, Mirzapur Road Ahmedabad Gujarat : 380001 <BR>Tel: 91-79-25507671/25507073 <BR>Email: ketanadhvaryu@sarabhai.co.in <BR>Website: http://www.ase.life

Who are in the management team of Ambalal Sarabhai?

As of March 2022, the management team of Ambalal Sarabhai includes Kartikeya V Sarabhai (Chairman & Wholetime Director), Anil H Parekh (Non Executive Director), Chaula Shastri (Whole-time Director), and several independent directors, among others, overseeing the company's strategic direction and governance.

As of March 2022, the management team of Ambalal Sarabhai includes the following individuals:<BR><BR>1. **Kartikeya V Sarabhai** - Chairman & Wholetime Director<BR>2. **Anil H Parekh** - Non Executive Director<BR>3. **Ashwin P Hathi** - Independent Director<BR>4. **Chaula Shastri** - Whole-time Director<BR>5. **Chandrashekhar B. Bohra** - Independent Director<BR>6. **Damodar Sejpal** - Company Secretary & Compliance Officer<BR>7. **Mayur K Swedia** - Independent Director<BR>8. **Brijesh Khandelwal** - Director and Additional Director<BR><BR>This team is responsible for the strategic direction and governance of the company.

When is the next results date for Ambalal Sarabhai?

No Upcoming Board Meetings

Has Ambalal Sarabhai declared dividend?

No Dividend History Available

Who are the peers of the Ambalal Sarabhai?

Ambalal Sarabhai's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Natural Capsules, Coral Labs, Kimia Bioscien, and Sat Kartar. While Sun Pharma and others show excellent management and growth, Ambalal Sarabhai has below-average performance, with a 1-year return of -21.20%.

Peers: The peers of Ambalal Sarabhai are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Natural Capsules, Coral Labs., Kimia Bioscien., Sat Kartar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Below Average management risk is found at Ambalal Sarabhai, Natural Capsules, Coral Labs., Kimia Bioscien., and Sat Kartar. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Ambalal Sarabhai and Kimia Bioscien., with the rest showing Good or Below Average growth. Excellent capital structure is seen in Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Coral Labs., while Good capital structure is noted for Ambalal Sarabhai, Natural Capsules, and Sat Kartar, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Ambalal Sarabhai has the lowest at -21.20%. Compared to its peers, Ambalal Sarabhai's return is significantly lower. Additionally, the six-month return is negative for Ambalal Sarabhai, Natural Capsules, Coral Labs., and Kimia Bioscien.

Is Ambalal Sarabhai overvalued or undervalued?

As of June 2, 2025, Ambalal Sarabhai is considered an attractive investment due to its undervalued status, with a PE ratio of 23.05, a PEG ratio of 0.28 indicating strong growth potential, and a competitive ROE of 8.52%, despite recent underperformance against the Sensex.

As of 2 June 2025, the valuation grade for Ambalal Sarabhai has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued, particularly given its price-to-earnings (PE) ratio of 23.05, a price-to-book value of 1.96, and an EV to EBITDA ratio of 38.95. These ratios suggest that the stock is trading at a reasonable valuation compared to its earnings and book value.<BR><BR>In comparison to its peers, Ambalal Sarabhai's PE ratio aligns closely with the industry average, while its PEG ratio of 0.28 indicates strong growth potential relative to its price. Notably, its return on equity (ROE) stands at 8.52%, which is competitive within the pharmaceuticals and biotechnology sector. Despite recent underperformance against the Sensex, particularly in the year-to-date and one-year periods, the overall valuation metrics suggest that Ambalal Sarabhai presents a compelling investment opportunity at its current price of 36.70.

What is the technical trend for Ambalal Sarabhai?

As of June 4, 2025, Ambalal Sarabhai's technical trend has shifted to bearish, driven by daily moving averages and Bollinger Bands indicating bearish conditions, despite mixed signals from the MACD and KST across different time frames.

As of 4 June 2025, the technical trend for Ambalal Sarabhai has changed from mildly bearish to bearish. The current stance is bearish with moderate strength, primarily driven by the daily moving averages indicating a bearish trend and both weekly and monthly Bollinger Bands also signaling bearish conditions. The MACD shows a mildly bullish signal on the weekly chart but is mildly bearish on the monthly, suggesting mixed signals across time frames. The KST aligns with this by being mildly bullish weekly but mildly bearish monthly. Overall, the indicators reflect a bearish sentiment, particularly in the short-term daily analysis.

Who are the top shareholders of the Ambalal Sarabhai?

The top shareholders of Ambalal Sarabhai are Sarabhai Holdings Private Limited with 25.76%, individual investors with 57.42%, and Haryana Containers Limited as the largest public shareholder at 1.61%. There are no pledged promoter holdings or mutual funds involved.

The top shareholders of Ambalal Sarabhai include Sarabhai Holdings Private Limited, which holds the highest stake at 25.76%. Individual investors collectively own 57.42% of the company. Additionally, Haryana Containers Limited is the highest public shareholder with a holding of 1.61%. There are also two foreign institutional investors (FIIs) with a combined holding of 0.38%. Notably, there are no pledged promoter holdings and no mutual funds currently holding shares in the company.

Are Ambalal Sarabhai latest results good or bad?

Ambalal Sarabhai Enterprises' latest results show a significant increase in Profit After Tax (PAT) to Rs 8.22 crore, up 175.6% from previous quarters, but also a decline in net sales to Rs 40.34 crore, down 17.7%, and negative cash flow of Rs -17.62 crore. Overall, while PAT growth is positive, the drop in sales and cash flow indicates the company is facing serious challenges.

The latest results for Ambalal Sarabhai Enterprises present a mixed picture. On one hand, the company achieved a Profit After Tax (PAT) of Rs 8.22 crore, which is a remarkable increase of 175.6% compared to the average PAT from the previous four quarters. This is the highest PAT the company has recorded in the last five quarters, and it has led to an increase in Earnings per Share (EPS) to Rs 1.07.<BR><BR>However, there are significant challenges as well. The company reported a Profit Before Tax (PBT) of Rs -0.43 crore, which indicates a substantial decline from previous averages. Additionally, net sales fell to Rs 40.34 crore, down 17.7% from prior averages, marking the lowest sales in five quarters. The operating profit also saw a sharp decline, and cash flow from operations remained negative at Rs -17.62 crore, the lowest in three years.<BR><BR>Overall, while the PAT growth is a positive highlight, the drop in sales and negative cash flow suggest that the company is facing considerable difficulties. Therefore, the financial performance can be seen as flat and somewhat concerning, given the contrasting trends in profitability and sales.

How has been the historical performance of Ambalal Sarabhai?

Ambalal Sarabhai's historical performance shows fluctuating results, with net sales increasing from 170.28 crore in March 2023 to 196.19 crore in March 2025, but profitability declined significantly, with profit after tax falling from 12.14 crore to 4.29 crore and negative cash flow from operating activities. Total liabilities and assets both rose, indicating a stable asset base despite financial challenges.

Answer:<BR>The historical performance of Ambalal Sarabhai shows a fluctuating trend in key financial metrics over the years, with notable changes in revenue and profitability.<BR><BR>Breakdown:<BR>Ambalal Sarabhai's net sales increased from 170.28 crore in March 2023 to 196.19 crore in March 2025, reflecting a growth trend. However, the total operating income showed a decline from 196.75 crore in March 2022 to 196.19 crore in March 2025. The company's total expenditure, excluding depreciation, rose from 161.71 crore in March 2023 to 188.10 crore in March 2025, impacting operating profit, which decreased from 21.06 crore in March 2023 to 19.47 crore in March 2025. Profit before tax also declined from 15.86 crore in March 2023 to 4.19 crore in March 2025, while profit after tax fell from 12.14 crore to 4.29 crore in the same period. The consolidated net profit showed a similar downward trend, decreasing from 11.45 crore in March 2023 to 4.93 crore in March 2025. On the balance sheet, total liabilities increased from 245.74 crore in March 2023 to 268.23 crore in March 2025, while total assets rose from 245.74 crore to 268.23 crore, indicating a stable asset base despite rising liabilities. Cash flow from operating activities turned negative, dropping from 5 crore in March 2023 to -17 crore in March 2025, which reflects challenges in cash generation. Overall, while revenue showed some growth, profitability and cash flow faced significant pressures during this period.

Should I buy, sell or hold Ambalal Sarabhai?

Which are the latest news on Ambalal Sarabhai?

Why is Ambalal Sarabhai falling/rising?

As of 04-Dec, Ambalal Sarabhai Enterprises Ltd's stock price is slightly rising at 27.78, but it has significantly underperformed the Sensex with a year-to-date decline of 48.15%. The stock remains below its moving averages and is near its 52-week low, indicating ongoing challenges despite the recent uptick.

As of 04-Dec, Ambalal Sarabhai Enterprises Ltd's stock price is experiencing a slight rise, currently at 27.78, with a change of 0.02 (0.07%) upward. This increase follows a trend reversal after two consecutive days of decline. However, it is important to note that the stock has been underperforming compared to the benchmark Sensex over various periods, with a year-to-date decline of 48.15% against a 9.12% increase in the Sensex.<BR><BR>Despite the current uptick, the stock is trading below its moving averages across multiple time frames, indicating a bearish trend. Additionally, investor participation has decreased, with delivery volume falling by 15.23% compared to the 5-day average. The stock is also close to its 52-week low, being only 2.45% away from a low of Rs 27.1. Overall, while there is a minor rise today, the broader context shows significant challenges for the stock, including poor performance over the past year and reduced trading activity.